



Express Mail No.: EL 564 157 764 US *ist*

#8
Ambr. w/ Seq.
11/29/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young et al.

Application No.: 09/724,396

Group Art Unit: 1648

Filed: November 28, 2000

Examiner: Brown, S

For: METHODS OF ADMINISTERING/
DOSING ANTI-RSV ANTIBODIES
FOR PROPHYLAXIS AND
TREATMENT

Attorney Docket No.: 10271-007

RECEIVED

NOV 27 2001

TECH CENTER 1600/2900

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

*Seq. list
played
before ds*

In response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures ("Notice") mailed May 22, 2001, a copy of which is submitted herewith, and in accordance with 37 C.F.R. § 1.821, Applicants, in connection with the above-identified patent application, submit herewith a Sequence Listing in paper and computer readable format pursuant to 37 C.F.R. § 1.821(c) and (e). Applicants also submit herewith: (1) a Petition For Extension Of Time (in duplicate) for 5 months to respond to the Notice; and (2) a Preliminary Amendment Under 37 C.F.R. § 1.115 with Exhibits A-C.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same. In accordance with 37 C.F.R. § 1.821(g), I hereby state that the submission filed herewith does not include new matter.

It is estimated that no additional fee is required for filing this response. In the event that an additional fee is required, please charge Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,


Date: November 23, 2001

Anthony M. Insogna 35,203
Anthony M. Insogna (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures

By: Jennifer J. Chedea
Reg No. 46,617



Application No.: 09/724,396

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE